The Hepatitis Viral Status in Patients With Hepatocellular Carcinoma: a Study of 3843 Patients From Taiwan Liver Cancer Network

Il-Chi Chang, Shiu-Feng Huang, Pei-Jer Chen, Chi-Ling Chen, Chao-Long Chen, Cheng-Chung Wu, Cheng-Chung Tsai, Po-Huang Lee, Miin-Fu Chen, Chuan-Mo Lee, Hsien-Chung Yu, Gin-Ho Lo, Chau-Ting Yeh, Chih-Chen Hong, Hock-Liew Eng, John Wang, Hui-Hwa Tseng, Cheng-Hsiang Hsiao, Hong-Dar Isaac Wu, Tseng-Chang Yen, Yun-Fan Liaw, Il-Chi Chang, Shiu-Feng Huang, Pei-Jer Chen, Chi-Ling Chen, Chao-Long Chen, Cheng-Chung Wu, Cheng-Chung Tsai, Po-Huang Lee, Miin-Fu Chen, Chuan-Mo Lee, Hsien-Chung Yu, Gin-Ho Lo, Chau-Ting Yeh, Chih-Chen Hong, Hock-Liew Eng, John Wang, Hui-Hwa Tseng, Cheng-Hsiang Hsiao, Hong-Dar Isaac Wu, Tseng-Chang Yen, Yun-Fan Liaw

Abstract

Hepatocellular carcinoma (HCC) is the leading cancer death in Taiwan. Chronic viral hepatitis infections have long been considered as the most important risk factors for HCC in Taiwan. The previously published reports were either carried out by individual investigators with small patient numbers or by large endemic studies with limited viral marker data. Through collaboration with 5 medical centers across Taiwan, Taiwan liver cancer network (TLCN) was established in 2005. All participating centers followed a standard protocol to recruit liver cancer patients along with their biosamples and clinical data. In addition, detailed viral marker analysis for hepatitis B virus (HBV) and hepatitis C virus (HCV) were also performed. This study included 3843 HCC patients with available blood samples in TLCN (recruited from November 2005 to April 2011). There were 2153 (56.02%) patients associated with HBV (HBV group); 969 (25.21%) with HCV (HCV group); 310 (8.07%) with both HBV and HCV (HBV+HCV group); and 411 (10.69%) were negative for both HBV and HCV (non-B non-C group). Two hundred two of the 2463 HBV patients (8.20%) were HBsAg(-), but HBV DNA (+). The age, gender, cirrhosis, viral titers, and viral genotypes were all significantly different between the above 4 groups of patients. The median age of the HBV group was the youngest, and the cirrhotic rate was lowest in the non-B non-C group (only 25%). This is the largest detailed viral hepatitis marker study for HCC patients in the English literatures. Our study provided novel data on the interaction of HBV and HCV in the HCC patients and also confirmed that the HCC database of TLCN is highly representative for Taiwan and an important resource for HCC research.

Conflict of interest statement

All authors have no conflict of interest to declare.

Figures

FIGURE 1
FIGURE 1
The location of the 5 collaborating medical centers and the central tissue bank at National Health Research Institutes are shown on the map of Taiwan.

References

    1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69–90.
    1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365:1118–1127.
    1. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010; 7:448–458.
    1. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12:S294–S308.
    1. Liaw YF, Tai DI, Chu CM, et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 1986; 90:263–267.
    1. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997; 336:1855–1859.
    1. Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year follow-up study. J Natl Cancer Inst 2009; 101:1348–1355.
    1. Department of Health, Executive Yuan, R.O.C. 2011. Statistics of Causes of Death. .
    1. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993; 262:369–370.
    1. Lee CM, Lu SN, Changchien CS, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999; 86:1143–1150.
    1. Chen YJ, Yeh SH, Chen JT, et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 2000; 119:431–440.
    1. Yeh SH, Chen PJ, Shau WY, et al. Chromosomal allelic imbalance evolving from liver cirrhosis to hepatocellular carcinoma. Gastroenterology 2001; 121:699–709.
    1. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347:168–174.
    1. Lu SN, Su WW, Yang SS, et al. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer 2006; 119:1946–1952.
    1. Chuang WL, Chang WY, Lu SN, et al. The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area: a case-control study. Cancer 1992; 69:2052–2054.
    1. Lu SN, Chue PY, Chen HC, et al. Different viral aetiology of hepatocellular carcinoma between two hepatitis B and C endemic townships in Taiwan. J Gastroenterol Hepatol 1997; 12:547–550.
    1. Chen CH, Huang GT, Yang PM, et al. Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis. Eur J Cancer 2006; 42:2524–2529.
    1. Lok ASF, McMahon BJ. AASLD Practice guidelines: Chronic hepatitis B. Hepatology 2007; 45:507–539.
    1. Lee MH, Lu SN, Yuan Y, et al. Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. PLoS One 2014; 9:e94760.
    1. Kiyosawa K, Umemura T, Ichijo T, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004; 127:S17–S26.
    1. Chen CH, Yang PM, Huang GT, et al. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007; 106:148–155.
    1. Sun CA, Chen HC, Lu SN, et al. Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors. J Med Virol 2001; 65:30–34.
    1. Liaw YF, Tsai SL, Chang JJ, et al. Displacement of hepatitis B virus by hepatitis C virus as the cause of continuing chronic hepatitis. Gastroenterology 1994; 106:1048–1053.
    1. Dai CY, Yu ML, Chuang WL, et al. Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2001; 16:636–640.
    1. Sagnelli E, Coppola N, Messina V, et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 2002; 36:1285–1291.
    1. Chu CM, Yeh CT, Sheen IS, et al. Acute hepatitis C virus (HCV) infection in chronic carriers of hepatitis B virus (HBV): the impact of underlying active HBV replication on persistence of HCV infection and antibody responses to HCV. Gut 2002; 51:95–99.
    1. Sagnelli E, Coppola N, Marrocco C, et al. Hepatitis C virus superinfection in hepatitis B virus chronic carriers: a reciprocal viral interaction and a variable clinical course. J Clin Virol 2006; 35:317–320.
    1. Ahn SH, Park YN, Park JY, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 2005; 42:188–194.
    1. Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 2006; 119:71e9–e16.
    1. Liu J, Yang HI, Lee MH, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010; 139:474–482.
    1. Hsu CW, Yeh CT, Chang ML, et al. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. Gastroenterology 2007; 132:543–550.
    1. Hsu CW, Yeh CT. Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy. Hepatology 2011; 54:101–108.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다